| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2003;75:S58-S65
© 2003 The Society of Thoracic Surgeons
a College of Physicians and Surgeons of Columbia University, New York, New York, USA
* Address reprint requests to Dr Itescu, Transplantation Immunology, Department of Surgery, College of Physicians & Surgeons of Columbia University, 622 West 168th St, P&S 14-402, New York, NY 10032, USA.
e-mail: si5{at}columbia.edu
Presented at the Heart Failure & Circulatory Support Summit, Cleveland, OH, Aug 22–25, 2002.
Abstract
The unquestionable clinical success of left ventricular assist device (LVAD) implantation has, nevertheless, been accompanied by complications arising from interactions between the implanted biomaterial and the host immune system. The aberrant state of monocyte and T-cell activation resulting from these host/device interactions is accompanied by two parallel processes: (1) selective loss of Th1 cytokine producing CD4 T-cells through activation-induced cell death; and (2) unopposed activation of Th2 cytokine producing CD4 T-cells resulting in B-cell hyperreactivity and dysregulated immunoglobulin synthesis through Th2 cytokines and heightened CD40 ligand-CD40 interactions. The net results of these events is that, on the one hand, the LVAD recipient develops progressive defects in cellular immunity and is at increased risk of serious infection, and, on the other hand, is more likely to develop allosensitization, posing a significant risk to successful transplant outcome. Intravenous immunoglobulin therapy is an effective and safe modality for sensitized LVAD recipients awaiting cardiac transplantation, reducing serum anti–human lymphoicyte antigen (HLA) alloreactivity and shortening the duration to transplantation. The therapeutic and safety profile of intravenous immunoglobulin would appear to be superior to plasmapheresis. Immunosuppression incorporating intravenous cyclophosphamide before and after transplantation is safe and highly effective in sensitized LVAD recipients of cardiac transplantation. When used after transplantation as part of triple immunosuppressive regimens, cyclophosphamide is superior to mycophenolate mofetil in reducing episodes of allograft rejection in these patients. Because these immune dysfunctions appear to be related to the effects of excessive biomaterial-associated T-cell activation, future efforts will need to be directed at either altering the physical properties of the materials interacting with the host circulation or pharmacological intervention aimed more selectively at inhibiting T-cell activation.
This article has been cited by other articles:
|
|
 |
|
  I. George, P. Colley, M. J. Russo, T. P. Martens, E. Burke, M. C. Oz, M. C. Deng, D. M. Mancini, and Y. Naka Association of device surface and biomaterials with immunologic sensitization after mechanical support. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1372 - 1379.e1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Kimball, M. Flattery, F. McDougan, and V. Kasirajan Cellular immunity impaired among patients on left ventricular assist device for 6 months. Ann. Thorac. Surg., May 1, 2008; 85(5): 1656 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]
|
|
|
|
|
|
S. Aggarwal, F. Cheema, M. C. Oz, and Y. Naka Long-Term Mechanical Circulatory Support Card. Surg. Adult, January 1, 2008; 3(2008): 1609 - 1628. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
